Clinical study of multiple myeloma in the elderly

J. Tomiyama; H. Kudo; N. Nakamura; Y. Murai; S. Tsunadori; Y. Muto; A. Urabe; M. Mori; N. Tsuruoka; T. Shirai; M. Kawado; Y. Adachi; T. Shirakura; H. Yamaguchi; H. Katsunuma

doi:10.3892/or.2.4.669

Clinical study of multiple myeloma in the elderly

J. Tomiyama, H. Kudo, N. Nakamura, Y. Murai, S. Tsunadori, Y. Muto, A. Urabe, M. Mori, N. Tsuruoka, T. Shirai, M. Kawado, Y. Adachi, T. Shirakura, H. Yamaguchi, H. Katsunuma

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

From January 1989 until December 1992, 120 elderly patients over 65 years old with multiple myeloma (MM) were enrolled with the Elderly Hematology Study Group (EHSG) with 14 institutions participating. Several courses of chemotherapy were conducted in 103 of the 120 patients, 33 patients with α-interferon (IFN) and 70 patients without IFN. The response rate (CR+PR) was 24.0% of all 120 cases, 24.2% of the group treated with IFN and 25.7% of those treated without IFN. Similarly, the efficacy rate (CR+PR+MR) of these groups were 78.8%, 81.8% and 78.8%, respectively. The 50% survival time was 31 months in the 120 cases as a whole, 44 months in the group treated with IFN and 38 months in the group treated without IFN. No significant difference was observed either in response rate (p=0.243) or survival time (p=0.262) in the groups treated with or without IFN.

Original language	English
Pages (from-to)	669-673
Number of pages	5
Journal	Oncology reports
Volume	2
Issue number	4
DOIs	https://doi.org/10.3892/or.2.4.669
Publication status	Published - 1995
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/or.2.4.669

Cite this

@article{f5ee1c2e21e4468fb93380940e617dea,

title = "Clinical study of multiple myeloma in the elderly",

abstract = "From January 1989 until December 1992, 120 elderly patients over 65 years old with multiple myeloma (MM) were enrolled with the Elderly Hematology Study Group (EHSG) with 14 institutions participating. Several courses of chemotherapy were conducted in 103 of the 120 patients, 33 patients with α-interferon (IFN) and 70 patients without IFN. The response rate (CR+PR) was 24.0% of all 120 cases, 24.2% of the group treated with IFN and 25.7% of those treated without IFN. Similarly, the efficacy rate (CR+PR+MR) of these groups were 78.8%, 81.8% and 78.8%, respectively. The 50% survival time was 31 months in the 120 cases as a whole, 44 months in the group treated with IFN and 38 months in the group treated without IFN. No significant difference was observed either in response rate (p=0.243) or survival time (p=0.262) in the groups treated with or without IFN.",

author = "J. Tomiyama and H. Kudo and N. Nakamura and Y. Murai and S. Tsunadori and Y. Muto and A. Urabe and M. Mori and N. Tsuruoka and T. Shirai and M. Kawado and Y. Adachi and T. Shirakura and H. Yamaguchi and H. Katsunuma",

year = "1995",

doi = "10.3892/or.2.4.669",

language = "English",

volume = "2",

pages = "669--673",

journal = "Oncology reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "4",

}

TY - JOUR

T1 - Clinical study of multiple myeloma in the elderly

AU - Tomiyama, J.

AU - Kudo, H.

AU - Nakamura, N.

AU - Murai, Y.

AU - Tsunadori, S.

AU - Muto, Y.

AU - Urabe, A.

AU - Mori, M.

AU - Tsuruoka, N.

AU - Shirai, T.

AU - Kawado, M.

AU - Adachi, Y.

AU - Shirakura, T.

AU - Yamaguchi, H.

AU - Katsunuma, H.

PY - 1995

Y1 - 1995

N2 - From January 1989 until December 1992, 120 elderly patients over 65 years old with multiple myeloma (MM) were enrolled with the Elderly Hematology Study Group (EHSG) with 14 institutions participating. Several courses of chemotherapy were conducted in 103 of the 120 patients, 33 patients with α-interferon (IFN) and 70 patients without IFN. The response rate (CR+PR) was 24.0% of all 120 cases, 24.2% of the group treated with IFN and 25.7% of those treated without IFN. Similarly, the efficacy rate (CR+PR+MR) of these groups were 78.8%, 81.8% and 78.8%, respectively. The 50% survival time was 31 months in the 120 cases as a whole, 44 months in the group treated with IFN and 38 months in the group treated without IFN. No significant difference was observed either in response rate (p=0.243) or survival time (p=0.262) in the groups treated with or without IFN.

AB - From January 1989 until December 1992, 120 elderly patients over 65 years old with multiple myeloma (MM) were enrolled with the Elderly Hematology Study Group (EHSG) with 14 institutions participating. Several courses of chemotherapy were conducted in 103 of the 120 patients, 33 patients with α-interferon (IFN) and 70 patients without IFN. The response rate (CR+PR) was 24.0% of all 120 cases, 24.2% of the group treated with IFN and 25.7% of those treated without IFN. Similarly, the efficacy rate (CR+PR+MR) of these groups were 78.8%, 81.8% and 78.8%, respectively. The 50% survival time was 31 months in the 120 cases as a whole, 44 months in the group treated with IFN and 38 months in the group treated without IFN. No significant difference was observed either in response rate (p=0.243) or survival time (p=0.262) in the groups treated with or without IFN.

UR - http://www.scopus.com/inward/record.url?scp=0029060577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029060577&partnerID=8YFLogxK

U2 - 10.3892/or.2.4.669

DO - 10.3892/or.2.4.669

M3 - Article

AN - SCOPUS:0029060577

SN - 1021-335X

VL - 2

SP - 669

EP - 673

JO - Oncology reports

JF - Oncology reports

IS - 4

ER -

Clinical study of multiple myeloma in the elderly

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this